Baike Bio’s RSV antibody cocktail trial application accepted by Chinese regulator
Baike Bio (百克生物), a subsidiary of Changchun High-Tech, announced its clinical trial application for a recombinant human anti-RSV monoclonal antibody injection combination formulation has been accepted by China’s National Medical Products Administration. The product is intended to prevent lower respiratory tract infections in newborns and infants. Preclinical studies indicate good efficacy and safety, with a single dose expected to cover an entire RSV season. The cocktail formulation differs from four currently approved single-component RSV antibodies in China.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Reporting timeline
BaiKe Bio's RSV Antibody Product Clinical Trial Application Accepted, Adding Innovation to Pipeline
On September 22, BaiKe Biological (百克生物) announced that its clinical trial application for a respiratory syncytial virus (RSV) antibody product has been accepted by Chinese regulators. RSV is a major cause of lower respiratory tract infections in newborns and infants, with significant unmet preventive needs. The product is a combination formulation, distinct from the four existing single RSV antibody products on the Chinese market. Preclinical studies indicate good efficacy and controllable safety, and the product is designed to cover an entire RSV season with a single dose, potentially improving convenience and compliance for infants. This application marks progress in BaiKe Bio's parallel vaccine and monoclonal antibody R&D matrix. If clinical trials proceed smoothly, the product could enrich the company's innovative product pipeline, strengthen its presence in pediatric infectious disease prevention, and support long-term growth. The report is sourced from Shanghai Securities News.
Read sourceBaike Biological RSV Antibody Combination Preparation Clinical Trial Application Accepted
Baike Biological's clinical trial application for a respiratory syncytial virus (RSV) antibody combination preparation has been accepted by Chinese regulators, according to a report by Shanghai Securities News. RSV is a major cause of respiratory infections across all age groups, with severe impacts on infants, the elderly, and high-risk adults. The antibody is designed to prevent lower respiratory tract infections caused by RSV in newborns and infants. Preclinical studies indicate good efficacy and acceptable safety, with a single dose covering an entire RSV season. The company notes that this product is a cocktail combination preparation, offering stronger neutralizing activity compared to the four currently approved single-component RSV antibodies in China (two imported, two domestic). Baike Biological stated that the acceptance of the application reflects its innovation capabilities and, if successful, will help optimize its product structure and enhance long-term profitability.
Read sourceChangchun High-Tech unit's RSV antibody clinical trial application accepted by Chinese regulator
Changchun High-Tech (000661.SZ) announced that its subsidiary, Baike Bio, has received an acceptance notice from China's National Medical Products Administration for a clinical trial application of a recombinant human anti-respiratory syncytial virus (RSV) monoclonal antibody injection combination formulation. The RSV antibody is designed to prevent lower respiratory tract infections caused by RSV in newborns and infants. Preclinical pharmacodynamic studies indicate good efficacy, and toxicology studies show the product is well-tolerated and safe. A key feature is that a single dose is expected to cover an entire RSV season, potentially improving patient compliance and convenience of prevention.
Read sourceShow 2 older updatesHide older updates
BCHT's RSV Antibody Injection Clinical Trial Application Accepted by China's NMPA
BCHT Biotechnology Co. (百克生物) announced that it has received a formal acceptance notice from China's National Medical Products Administration (NMPA) for its clinical trial application regarding a recombinant humanized anti-respiratory syncytial virus (RSV) monoclonal antibody injection combination formulation. The application, filed under the category of domestic drug production registration clinical trials, has been granted the acceptance number CXSL2601038. The product is intended for the prevention of lower respiratory tract infections caused by RSV in newborns and infants. The acceptance signifies that the NMPA has reviewed the submission and deemed it complete for further evaluation, moving the drug candidate one step closer to clinical testing in China.
Read sourceBCHT's RSV antibody cocktail injection clinical trial application accepted in China
On the evening of September 22, BCHT (Baike Bio) announced that its clinical trial application for a recombinant human anti-respiratory syncytial virus (RSV) monoclonal antibody injection combination formulation has been accepted by Chinese regulators. The RSV antibody is intended to prevent lower respiratory tract infections caused by RSV in newborns and infants. According to the company, as of the disclosure date, four RSV antibodies have been approved for marketing in China, two imported and two domestic, all of which are single-component products. BCHT's accepted antibody is a cocktail combination formulation, which the company claims has stronger neutralizing activity compared to single-component antibody preparations. The announcement was sourced from the Beijing Business Today.
Read source